Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial

Prior attempts to escalate radiation dose for non–small cell lung cancer (NSCLC) have not improved survival. Given the high risk for cardiopulmonary toxicity with treatment and heterogenous presentation of locally advanced NSCLC, it is unlikely that a single dose regimen is optimal for all patients....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical lung cancer 2024-03, Vol.25 (2), p.186-189
Hauptverfasser:	Hui, Caressa, Brown, Eleanor, Wong, Samantha, Das, Millie, Wakelee, Heather, Neal, Joel, Ramchandran, Kavitha, Myall, Nathaniel J., Pham, Daniel, Xing, Lei, Yang, Yong, Kovalchuk, Nataliya, Yuan, Ying, Lu, Ying, Xiang, Michael, Chin, Alex, Diehn, Maximilian, Loo, Billy W., Vitzthum, Lucas K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bayes Theorem Carcinoma, Non-Small-Cell Lung - drug therapy Chemoradiotherapy - methods Clinical trial Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Dose escalation Humans Isotoxic radiation Lung Lung Neoplasms - drug therapy Personalized medicine Personalized radiation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!